These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 35053487)

  • 1. Two Doses of BNT162b2 mRNA Vaccine in Patients after Hematopoietic Stem Cell Transplantation: Humoral Response and Serological Conversion Predictors.
    Majcherek M; Matkowska-Kocjan A; Szymczak D; Karasek M; Szeremet A; Kiraga A; Milanowska A; Kuznik E; Kujawa K; Wrobel T; Szenborn L; Czyz A
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation.
    Yeshurun M; Pasvolsky O; Shargian L; Yahav D; Ben-Zvi H; Rubinstein M; Sela-Navon M; Wolach O; Raanani P; Rozovski U
    Clin Microbiol Infect; 2022 Feb; 28(2):303.e1-303.e4. PubMed ID: 34715348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring Humoral Response Following BNT162b2 mRNA Vaccination against SARS-CoV-2 in Hematopoietic Stem-Cell Transplantation Patients: A Single-Center Prospective Study along with a Brief Review of Current Literature.
    Asimakopoulos JV; Lalou E; Seferlis G; Malliarou M; Konstantinou E; Drandakis I; Vasilopoulos I; Georgopoulou AN; Kopsaftopoulou A; Machairas A; Piperidou A; Karapaschalidis A; Lefaki ME; Galopoulos D; Arapaki MP; Petsa P; Benekou E; Siakantaris MP; Papavassiliou AG; Tsaftaridis P; Panayiotidis P; Vassilakopoulos TP; Papapanagiotou A; Angelopoulou MK
    Hematol Rep; 2024 Apr; 16(2):220-233. PubMed ID: 38651451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.
    Bergman P; Blennow O; Hansson L; Mielke S; Nowak P; Chen P; Söderdahl G; Österborg A; Smith CIE; Wullimann D; Vesterbacka J; Lindgren G; Blixt L; Friman G; Wahren-Borgström E; Nordlander A; Gomez AC; Akber M; Valentini D; Norlin AC; Thalme A; Bogdanovic G; Muschiol S; Nilsson P; Hober S; Loré K; Chen MS; Buggert M; Ljunggren HG; Ljungman P; Aleman S;
    EBioMedicine; 2021 Dec; 74():103705. PubMed ID: 34861491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment.
    Peeters M; Verbruggen L; Teuwen L; Vanhoutte G; Vande Kerckhove S; Peeters B; Raats S; Van der Massen I; De Keersmaecker S; Debie Y; Huizing M; Pannus P; Neven K; Ariën KK; Martens GA; Van Den Bulcke M; Roelant E; Desombere I; Anguille S; Goossens M; Vandamme T; van Dam P
    ESMO Open; 2021 Oct; 6(5):100274. PubMed ID: 34597941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 mRNA Vaccine Tolerance and Immunogenicity in Hematopoietic Stem Cell Transplantation Recipients Aged 5-11 Years Old-Non-Randomized Clinical Trial.
    Matkowska-Kocjan A; Owoc-Lempach J; Ludwikowska K; Szenborn F; Moskwa N; Kurek K; Kałwak K; Szenborn L; Ussowicz M
    Vaccines (Basel); 2023 Jan; 11(1):. PubMed ID: 36680039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of a third dose of anti-SARS-CoV-2 vaccine in hematopoietic cell transplant recipients: A Japanese multicenter observational study.
    Mori Y; Uchida N; Wake A; Miyawaki K; Eto T; Nakamura T; Iwasaki H; Ito Y; Tanimoto K; Katayama Y; Imamura Y; Takahashi T; Fujisaki T; Kamimura T; Choi I; Ishitsuka K; Yoshimoto G; Ogawa R; Sugita J; Takamatsu Y; Tanimoto K; Hidaka T; Miyamoto T; Akashi K; Nagafuji K
    Vaccine; 2023 Nov; 41(47):6899-6903. PubMed ID: 37866994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients.
    Chiarucci M; Paolasini S; Isidori A; Guiducci B; Loscocco F; Capalbo M; Visani G
    Front Oncol; 2021; 11():737300. PubMed ID: 34552880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy-A Single-Center Prospective Cohort Study.
    Ram R; Hagin D; Kikozashvilli N; Freund T; Amit O; Bar-On Y; Beyar-Katz O; Shefer G; Moshiashvili MM; Karni C; Gold R; Kay S; Glait-Santar C; Eshel R; Perry C; Avivi I; Apel A; Benyamini N; Shasha D; Ben-Ami R
    Transplant Cell Ther; 2021 Sep; 27(9):788-794. PubMed ID: 34214738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
    Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
    Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Third Dose COVID-19 Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Patients.
    Watanabe M; Yakushijin K; Funakoshi Y; Ohji G; Ichikawa H; Sakai H; Hojo W; Saeki M; Hirakawa Y; Matsumoto S; Sakai R; Nagao S; Kitao A; Miyata Y; Koyama T; Saito Y; Kawamoto S; Yamamoto K; Ito M; Murayama T; Matsuoka H; Minami H
    Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Response to BNT162b2 in Solid Organ Transplant Recipients: Negative Impact of Mycophenolate and High Responsiveness of SARS-CoV-2 Recovered Subjects against Delta Variant.
    Cassaniti I; Bergami F; Arena F; Sammartino JC; Ferrari A; Zavaglio F; Curti I; Percivalle E; Meloni F; Pandolfi L; Pellegrini C; Turco A; Seminari E; Pattonieri EF; Gregorini M; Rampino T; Sarasini A; Lilleri D; Baldanti F
    Microorganisms; 2021 Dec; 9(12):. PubMed ID: 34946223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Status Against Hepatitis B in Patients After Allogeneic Hematopoietic Cell Transplantation-Factors Affecting Early and Long-Lasting Maintenance of Protective Anti-HBs Titers.
    Piekarska A; Wisniewski P; Lewandowski K; Gil L; Trzonkowski P; Bieniaszewska M; Zaucha JM
    Front Immunol; 2020; 11():586523. PubMed ID: 33335530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.
    Gil-Manso S; Carbonell D; López-Fernández L; Miguens I; Alonso R; Buño I; Muñoz P; Ochando J; Pion M; Correa-Rocha R
    Front Immunol; 2021; 12():726960. PubMed ID: 34671348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B Cell Composition Is Altered After Kidney Transplantation and Transitional B Cells Correlate With SARS-CoV-2 Vaccination Response.
    Schuller M; Pfeifer V; Kirsch AH; Klötzer KA; Mooslechner AA; Rosenkranz AR; Stiegler P; Schemmer P; Sourij H; Eller P; Prietl B; Eller K
    Front Med (Lausanne); 2022; 9():818882. PubMed ID: 35187002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexpectedly High Efficacy of SARS-CoV-2 BNT162b2 Vaccine in Liver versus Kidney Transplant Recipients-Is It Related to Immunosuppression Only?
    Nazaruk P; Monticolo M; Jędrzejczak AM; Krata N; Moszczuk B; Sańko-Resmer J; Pilecki T; Urbanowicz A; Florczak M; Pączek L; Foroncewicz B; Mucha K
    Vaccines (Basel); 2021 Dec; 9(12):. PubMed ID: 34960200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Waning Humoral Response 3 to 6 Months after Vaccination with the SARS-COV-2 BNT162b2 mRNA Vaccine in Dialysis Patients.
    Berar-Yanay N; Freiman S; Shapira M; Saffoury A; Elemy A; Hamze M; Elhaj M; Zaher M; Matanis L; Armaly ZA
    J Clin Med; 2021 Dec; 11(1):. PubMed ID: 35011801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.